Search

Displaying results 911 - 920 of 2454 in total
  1. Drug

    Repotrectinib

    go.drugbank.com/drugs/DB16826
    ApprovedInvestigational

    Repotrectinib is a next-generation tyrosine kinase inhibitor (TKI) specifically designed to address resistance in the treatment of non-small cell lung cancer (NSCLC), specifically due to mutations in the ROS1 gene. ROS1 mutations are one...

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  2. Drug

    Rhodamine B

    go.drugbank.com/drugs/DB16853
    Experimental

    Categories: P-glycoprotein substrates
  3. Drug

    Naringin

    go.drugbank.com/drugs/DB16859
    Experimental

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors
  4. Drug

    Tanshinone I

    go.drugbank.com/drugs/DB16886
    Experimental

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors
  5. Drug

    EP-0042

    go.drugbank.com/drugs/DB18120
    Investigational

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  6. Drug

    Ferroheme

    go.drugbank.com/drugs/DB18267
    Investigational

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors
  7. Drug

    Fenvalerate

    go.drugbank.com/drugs/DB18391
    Experimental

    Categories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP3A Inhibitors
  8. Drug

    Vamorolone

    go.drugbank.com/drugs/DB15114
    ApprovedInvestigational

    Vamorolone is a novel and fully synthetic glucocorticoid developed by Santhera Pharmaceuticals. It is used to manage inflammation and immune dysregulation in patients with Duchenne muscular dystrophy (DMD), a neuromuscular disorder chara...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inducers
  9. Drug

    Pozelimab

    go.drugbank.com/drugs/DB15218
    ApprovedInvestigational

    [A261120] Pozelimab is a human, monoclonal immunoglobulin G4<sup>P</sup> antibody against the terminal complement protein C5.

  10. Drug

    Olorofim

    go.drugbank.com/drugs/DB15245
    Investigational

    Olorofim is under investigation in clinical trial NCT03340597 (Assessment of Varying Oral Dosing Regimens for F901318 in Healthy Subjects).

    Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Substrates